1. Home
  2. JWEL vs DRMA Comparison

JWEL vs DRMA Comparison

Compare JWEL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JWEL
  • DRMA
  • Stock Information
  • Founded
  • JWEL 2012
  • DRMA 2014
  • Country
  • JWEL China
  • DRMA United States
  • Employees
  • JWEL N/A
  • DRMA N/A
  • Industry
  • JWEL Other Consumer Services
  • DRMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • JWEL Consumer Discretionary
  • DRMA Health Care
  • Exchange
  • JWEL Nasdaq
  • DRMA Nasdaq
  • Market Cap
  • JWEL 4.1M
  • DRMA 4.5M
  • IPO Year
  • JWEL 2021
  • DRMA 2021
  • Fundamental
  • Price
  • JWEL $1.83
  • DRMA $5.98
  • Analyst Decision
  • JWEL
  • DRMA Strong Buy
  • Analyst Count
  • JWEL 0
  • DRMA 1
  • Target Price
  • JWEL N/A
  • DRMA $30.00
  • AVG Volume (30 Days)
  • JWEL 82.5K
  • DRMA 27.4K
  • Earning Date
  • JWEL 08-26-2025
  • DRMA 08-13-2025
  • Dividend Yield
  • JWEL N/A
  • DRMA N/A
  • EPS Growth
  • JWEL N/A
  • DRMA N/A
  • EPS
  • JWEL N/A
  • DRMA N/A
  • Revenue
  • JWEL $132,981,531.00
  • DRMA N/A
  • Revenue This Year
  • JWEL N/A
  • DRMA N/A
  • Revenue Next Year
  • JWEL N/A
  • DRMA N/A
  • P/E Ratio
  • JWEL N/A
  • DRMA N/A
  • Revenue Growth
  • JWEL N/A
  • DRMA N/A
  • 52 Week Low
  • JWEL $1.18
  • DRMA $5.74
  • 52 Week High
  • JWEL $3.71
  • DRMA $24.90
  • Technical
  • Relative Strength Index (RSI)
  • JWEL 40.05
  • DRMA 41.48
  • Support Level
  • JWEL $1.76
  • DRMA $5.75
  • Resistance Level
  • JWEL $2.05
  • DRMA $6.58
  • Average True Range (ATR)
  • JWEL 0.17
  • DRMA 0.61
  • MACD
  • JWEL -0.03
  • DRMA -0.07
  • Stochastic Oscillator
  • JWEL 24.00
  • DRMA 14.56

About JWEL Jowell Global Ltd.

Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing. Geographically, it generates all of its revenue from the PRC.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: